Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Kidney Blood Press Res ; 44(6): 1363-1371, 2019.
Article in English | MEDLINE | ID: mdl-31751997

ABSTRACT

BACKGROUND: In patients with renal failure, gadolinium-based contrast agents (GBCA) can be removed by intermittent hemodialysis (iHD) to prevent possible toxic effects. There is no data on the efficacy of GBCA removal via sustained low efficiency daily dialysis (SLEDD) which is mainly used in intensive care unit (ICU) patients. METHODS: We compared the elimination of the GBCA gadobutrol in 6 ICU patients treated with SLEDD (6-12 h, 90 L dialysate) with 7 normal ward inpatients treated with iHD (4 h, dialysate flow 500 mL/min). Both groups received 3 dialysis sessions on 3 consecutive days starting after the application of gadobutrol. Blood samples were drawn before and after each session and total dialysate, as well as urine was collected. Gadolinium (Gd) concentrations were measured using mass spectrometry and eliminated Gd was calculated from dialysate and urine. RESULTS: The initial mean plasma Gd concentration was 385 ± 183 µM for the iHD and 270 ± 97 µM for the SLEDD group, respectively (p > 0.05). The Gd-reduction rate after the first dialysis session was 83 ± 9 and 67 ± 9% for the iHD and the SLEDD groups, respectively (p = 0.0083). The Gd-reduction rate after the second and third dialysis was 94-98 and 89-96% for the iHD and the SLEDD groups (p > 0.05). The total eliminated Gd was 89 ± 14 and 91 ± 4% of the dose in the iHD and the SLEDD groups, respectively (p > 0.05). Gd dialyzer clearance was 95 ± 22 mL/min and 79 ± 19 mL/min for iHD and SLEDD, respectively (p > 0.05). CONCLUSIONS: Gd-elimination with SLEDD is equally effective as iHD and can be safely used to remove GBCA in ICU patients.


Subject(s)
Contrast Media/chemistry , Hybrid Renal Replacement Therapy/methods , Intermittent Renal Replacement Therapy/methods , Organometallic Compounds/isolation & purification , Renal Replacement Therapy/methods , Adult , Dialysis Solutions/chemistry , Female , Humans , Intensive Care Units , Male , Middle Aged , Organometallic Compounds/pharmacology , Renal Replacement Therapy/standards
2.
Kidney Blood Press Res ; 44(6): 1383-1391, 2019.
Article in English | MEDLINE | ID: mdl-31618744

ABSTRACT

BACKGROUND: Unplanned start of renal replacement therapy is common in patients with end-stage renal disease and often accomplished by hemodialysis (HD) using a central venous catheter (CVC). Urgent start using peritoneal dialysis (PD) could be an alternative for some of the patients; however, this requires a hospital-based PD center that offers a structured urgent start PD (usPD) program. METHODS: In this prospective study, we describe the implementation of an usPD program at our university hospital by structuring the process from presentation to PD catheter implantation and start of PD within a few days. For clinical validation, we compared the patient flow before (2013-2015) and after (2016-2018) availability of usPD. RESULTS: In the 3 years before the availability of usPD, 14% (n = 12) of incident PD patients (n = 87) presented in an unplanned situation and were initially treated with HD using a CVC. In the 3 years after implementation of the usPD program, 18% (n = 18) of all incident PD patients (n = 103) presented in an unplanned situation of whom n = 12 (12%) were treated with usPD and n = 6 (6%) with initial HD. usPD significantly reduced the use of HD by 57% (p = 0.0005). Hospital stay was similar in patients treated with usPD (median 9 days) compared to those with elective PD (8 days), and significantly lower than in patients with initial HD (26 days, p = 0.0056). CONCLUSIONS: Implementation of an usPD program reduces HD catheter use and hospital stay in the unplanned situation.


Subject(s)
Central Venous Catheters , Kidney Failure, Chronic/therapy , Length of Stay , Peritoneal Dialysis/methods , Renal Dialysis , Catheterization/methods , Catheterization/standards , Female , Humans , Male , Middle Aged , Peritoneal Dialysis/standards , Prospective Studies , Renal Dialysis/instrumentation
3.
BMC Infect Dis ; 15: 464, 2015 Oct 27.
Article in English | MEDLINE | ID: mdl-26503619

ABSTRACT

BACKGROUND: Nephropathia epidemica (NE) is a mild form of hemorrhagic fever with renal syndrome (HFRS) that is caused by the Puumala virus. Periodic outbreaks have been described in endemic areas, with a substantial number of previously healthy individuals developing acute kidney injury (AKI). There is a considerable diversity in the clinical course of the disease, and few patients require renal replacement therapy. METHODS: We tested whether urinary neutrophil gelatinase associated lipocalin (uNGAL), urine albumin/creatinine ratio (uACR), urine protein/creatinine ratio (uPCR), urine dipstick protein, C-reactive protein, procalcitonin, leukocyte and platelet count, determined on admission to the hospital, can predict the severity of AKI. Sixty-one patients were analyzed during admission in the emergency department. RESULTS: The variables most strongly associated with peak plasma creatinine concentration were uNGAL (ß = 0.70, p <0.0001), uPCR (ß = 0.64, p = 0.001), uACR (ß = 0.61, p = 0.002), and dipstick proteinuria (ß = 0.34, p = 0.008). The highest AUC-ROC to predict stage 3 AKI according to the acute kidney injury network's (AKIN) classification was seen for uNGAL (0.81, p = 0.001). CONCLUSION: uNGAL accurately predicts the severity of AKI in NE. This could help emergency room physicians predict disease severity and allow for initial risk stratification.


Subject(s)
Acute-Phase Proteins/urine , Hemorrhagic Fever with Renal Syndrome/etiology , Lipocalins/urine , Proteinuria/etiology , Proto-Oncogene Proteins/urine , Puumala virus/pathogenicity , Acute Kidney Injury/etiology , Acute Kidney Injury/urine , Acute Kidney Injury/virology , Adult , Albuminuria/etiology , Biomarkers/blood , Biomarkers/urine , C-Reactive Protein/analysis , Calcitonin , Calcitonin Gene-Related Peptide , Creatinine/blood , Emergency Service, Hospital , Female , Hemorrhagic Fever with Renal Syndrome/virology , Humans , Lipocalin-2 , Male , Middle Aged , Protein Precursors , Retrospective Studies
4.
Dtsch Med Wochenschr ; 139(15): 785, 2014 Apr.
Article in German | MEDLINE | ID: mdl-24691693

ABSTRACT

HISTORY AND ADMISSION FINDINGS: A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²). INVESTIGATIONS: Plasma creatinine concentration was elevated to 4.5 mg/dl. Upon detection of glucosuria and α1-microglobulinuria renal biopsy was performed. DIAGNOSIS, TREATMENT AND COURSE: Histologic analysis revealed massively injured tubules that could be explained by a toxic effect of ifosfamide. Glomeruli were not affected and appeared normal. After two months of conservative therapy, the patient developed an uremic syndrome requiring hemodialysis. Ever since kidney function did not recover albeit preserved diuresis. CONCLUSIONS: Ifosfamide can cause end-stage renal disease by a tubulotoxic effect that may be the result of a selective intracellular uptake into the proximal tubule via the human organic cation transporter 2 (OCT2).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Kidney Failure, Chronic/chemically induced , Kidney Failure, Chronic/diagnosis , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Aged , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Diagnosis, Differential , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Humans , Ifosfamide/adverse effects , Ifosfamide/therapeutic use , Male , Sarcoma/complications , Soft Tissue Neoplasms/complications , Treatment Outcome
5.
Dtsch Med Wochenschr ; 138(27): 1410, 2013 Jul.
Article in German | MEDLINE | ID: mdl-23801263

ABSTRACT

HISTORY AND ADMISSION FINDINGS: We report on a patient presenting with renal failure who developed mutliple episodes of flash pulmonary edema. INVESTIGATIONS: Volume retention due to ischemic nephropathy was found to be the cause. DIAGNOSIS, TREATMENT AND COURSE: She was diagnosed to have a high grade renal artery stenosis in a functional solitary kidney and underwent percutaneous angioplasty. After being anuric and dialysis-dependent, she regained her kidney function leading to resolution of the volume retention and could be weaned from dialysis. CONCLUSIONS: Ischemic nephropathy is often accompanied by recurrent episodes of flash pulmonary edema and responds well to an interventional treatment.


Subject(s)
Pulmonary Edema/diagnosis , Pulmonary Edema/etiology , Renal Artery Obstruction/complications , Renal Artery Obstruction/diagnosis , Renal Insufficiency/diagnosis , Renal Insufficiency/etiology , Aged , Diagnosis, Differential , Female , Humans , Pulmonary Edema/prevention & control , Renal Artery Obstruction/therapy , Renal Insufficiency/prevention & control
6.
Dtsch Med Wochenschr ; 138(6): 266, 2013 Feb.
Article in German | MEDLINE | ID: mdl-23361349

ABSTRACT

HISTORY AND ADMISSION FINDINGS: We report on a 58-year-old patient with weight loss, weakness and polyarthralgia. She reported of recurrent drops, painful joints and muscle weakness. INVESTIGATIONS: The patient had swollen joints, clubbing and cachexia. The radiogram of the hands and feet showed a hypertrophic oseoarthropathy. In further investigations we found a tumor in the upper left lung. The histology findings showed a adenocarcinoma of the lung. DIAGNOSIS, TREATMENT AND COURSE: The diagnosis of a secondary hypertrophic osteoarthropathy (Pierre Marie-Bamberger syndrome) due to a adenocarcinoma of the lung was made. The patient refused a radiochemotherapy and decided to go on vacation. Further course is unknown. CONCLUSIONS: Arthralgia is a common symptom for medical consultation. Pierre Marie-Bamberger syndrome is a rare cause of paraneoplastic arthritis. Notice that unspecific symptoms like weakness, weight loss and arthritis may result from paraneoplastic tumor disease.


Subject(s)
Adenocarcinoma/diagnosis , Arthralgia/etiology , Edema/diagnosis , Edema/etiology , Lung Neoplasms/diagnosis , Osteoarthropathy, Secondary Hypertrophic/etiology , Arthralgia/diagnosis , Female , Humans , Middle Aged , Muscle Weakness/etiology , Osteoarthropathy, Secondary Hypertrophic/diagnosis , Weight Loss
7.
Int J Nanomedicine ; 7: 4571-80, 2012.
Article in English | MEDLINE | ID: mdl-22942641

ABSTRACT

C60 nanoparticles, the so-called buckminsterfullerenes, have attracted great attention for medical applications as carriers, enzyme inhibitors or radical scavengers. However, publications evaluating their immunological mechanisms are still rather limited. Therefore, we aimed to analyze systematically the in vitro influence of polyhydroxy-C60 (poly-C60) and N-ethyl-polyamino-C60 (nepo-C60) on peripheral blood mononuclear cells (PBMC) from healthy individuals, angling their effect on proliferation, expression of surface markers, and cytokine production. We isolated PBMC from 20 healthy subjects and incubated them in a first step only with poly-C60 or nepo-C60, and in a second step together with recall antigens (purified protein derivative, tetanus toxoid, bacillus Calmette-Guérin). Proliferation was determined by (3)H-thymidine incorporation, activation of PBMC-subpopulations by flow cytometry by measurement of the activation marker CD69, and secretion of T helper cell type 1 (TH1)- (interferon-gamma [IFN-γ], tumor necrosis factor beta [TNF-ß]), TH2- (interleukin-5 [IL-5], -13, -10) and macrophage/monocyte-related cytokines (IL-1, IL-6, TNF-α) into the supernatants by enzyme-linked immunosorbent assay. Both fullerenes did not influence T cell reactivity, with no enhanced expression of CD69 and production of T cell cytokines observed, the CD4/CD8 ratio remaining unaffected. In contrast, they significantly enhanced the release of IL-6 and CD69-expression by CD56 positive natural killer cells. PBMC, which had been cultured together with the three recall antigens were not affected by both fullerenes at all. These data indicate that fullerenes do not interact with T cell reactivity but may activate cells of the innate immune system. Furthermore, they seem to act only on 'naïve' cells, which have not been prestimulated with recall antigens, there are however, large inter individual differences.


Subject(s)
Fullerenes/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Adaptive Immunity/drug effects , Adult , Antigens/immunology , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/metabolism , Female , Fullerenes/chemistry , Humans , Immunity, Innate/drug effects , Leukocytes, Mononuclear/metabolism , Male , Statistics, Nonparametric
SELECTION OF CITATIONS
SEARCH DETAIL
...